NCT01585688 2021-10-08
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
Gilead Sciences
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT01663766 2021-08-19
Phase I Study of Milatuzumab for Graft Versus Host Disease
Gilead Sciences
Phase 1 Terminated
NCT00421525 2021-08-16
Phase I/II Study of hLL1 in Multiple Myeloma
Gilead Sciences
Phase 1/2 Completed
NCT00504972 2018-05-29
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
Weill Medical College of Cornell University
Phase 1 Completed
NCT00989586 2017-02-06
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT00868478 2010-06-02
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Kaplan Medical Center
Phase 1/2 Unknown